SAN ANTONIO -- Preoperative radiotherapy (RT) plus PD-1 inhibitor pembrolizumab (Keytruda) significantly increased immune activation and tumor response in node-positive hormone receptor-positive (HR+) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback